Development of differential diagnosis for benign and malignant pheochromocytomas

International Journal of Urology

Volumn 15, Issue 9, 2008, Pages 771-777

  Gao, Baohua ^a   Kong, Fanshan ^a   Xu, Zhishun ^b  

^a Fourth Hospital of Jinan City   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Benign pheochromocytomas; Differentiating diagnosis; Genome studies; Malignant pheochromocytomas; Tumorigenesis

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; CHROMOGRANIN A; MOLECULAR MARKER; VASCULOTROPIN;

CANCER RISK; CARCINOGENESIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

ADRENAL GLAND NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; GENOME, HUMAN; HUMANS; PHEOCHROMOCYTOMA;

EID: 51549090381     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02111.x     Document Type: Review

References (58)

1. Allibhai Z, Rodrigues G, Brecevic E, Neumann HP, Winquist E. Malignant pheochromocytoma associated with germline mutation of the SDHB gene. J. Urol. 2004 172 : 1409 10.
2. Segawa N, Osafune T. Malignant pheochromocytoma of the urinary bladder. Hinyokika Kiyo 2005 51 : 291 6.
3. Ding SL, Sheu LF, Yu JC et al. Expression of estrogen receptor-alpha and Ki-67 in relation to pathological and molecular features in early-onset infiltrating ductal carcinoma. J. Biomed. Sci. 2004 11 : 911 19.
4. Eisenhofer G, Bornstein SR, Brouwers FM et al. Malignant pheochromocytoma: Current status and initiatives for future progress. Endocr. Relat. Cancer. 2004 11 : 423 36.
5. Giovanella L, Squin N, Ghelfo A, Ceriani L. Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: Comparison with plasma metanephrines and 123I-MIBG scan. Q. J. Nucl. Med. Mol. Imaging 2006 50 : 344 7.
6. Bertherat J, Gimenez-Roqueplo AP. New insights in the genetics of adrenocortical tumors, pheochromocytomas and paragangliomas. Horm. Metab. Res. 2005 37 : 384 90.
7. Ilias I, Yu J, Carrasquillo JA et al. Superiority of 6-[18F]- fluorodopamine positron emission tomography versus [131I]- metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J. Clin. Endocrinol. Metab. 2003 88 : 4083 7.
8. Nakatani T, Hayama T, Uchida J, Nakamura K, Takemoto Y, Sugimura K. Diagnostic localization of extra-adrenal pheochromocytoma: Comparison of (123)I-MIBG imaging and (131)I-MIBG imaging. Oncol. Rep. 2002 9 : 1225 7.
9. Hong R, Halama J, Bova D, Sethi A, Emami B. Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning. Int. J. Radiat. Oncol. Biol. Phys. 2007 67 : 720 6.
10. Chen YK, Su CT, Chi KH, Cheng RH, Wang SC, Hsu CH. Utility of 18F-FDG PET/CT uptake patterns in Waldeyer's ring for differentiating benign from malignant lesions in lateral pharyngeal recess of nasopharynx. J. Nucl. Med. 2007 48 : 8 14.
11. Bumming P, Nilsson B, Sorensen J, Nilsson O, Ahlman H. Use of 2-tracer PET to diagnose gastrointestinal stromal tumour and pheochromocytoma in patients with Carney triad and neurofibromatosis type 1. Scand. J. Gastroenterol. 2006 41 : 626 30.
12. Sood R, Story A, Rossleigh MA, Haindl W, Guille J, Pillai D. Superiority of F-18 FDG PET imaging for detection of a pheochromocytoma. Clin. Nucl. Med. 2006 31 : 13 5.
13. Ezuddin S, Fragkaki C. MIBG and FDG PET findings in a patient with malignant pheochromocytoma: A significant discrepancy. Clin. Nucl. Med. 2005 30 : 579 81.
14. Proye C, Fossati P, Fontaine P et al. Dopamine-secreting pheochromocytoma: An unrecognized entity? Classification of pheochromocytomas according to their type of secretion. Surgery 1986 100 : 1154 62.
15. John H, Ziegler WH, Hauri D, Jaeger P. Pheochromocytomas: Can malignant potential be predicted? Urology 1999 53 : 679 83.
16. Schlumberger M, Gicquel C, Lumbroso J et al. Malignant pheochromocytoma: Clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J. Endocrinol. Invest. 1992 15 : 631 42.
17. Plouin PF, Chatellier G, Fofol I, Corvol P. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 1997 29 : 1133 9.
18. van der Harst E, de Herder WW, de Krijger RR et al. The value of plasma markers for the clinical behaviour of phaeochromocytomas. Eur. J. Endocrinol. 2002 147 : 85 94.
19. Plouin PF, Gimenez-Roqueplo AP. Pheochromocytomas and secreting paragangliomas. Orphanet J. Rare Dis. 2006 1 : 49.
20. Rao F, Keiser HR, O'Connor DT. Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment. Hypertension 2000 36 : 1045 52.
21. O'Connor DT, Frigon RP. Chromogranin A, the major catecholamine storage vesicle soluble protein. Multiple size forms, subcellular storage, and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay. J. Biol. Chem. 1984 259 : 3237 47.
22. O'Connor DT, Klein RL, Thureson-Klein AK, Barbosa JA. Chromogranin A: localization and stoichiometry in large dense core catecholamine storage vesicles from sympathetic nerve. Brain Res. 1991 567 : 188 96.
23. Banks P, Helle KB. Chromogranins in sympathetic nerves. Philos. Trans. R. Soc. Lond B. Biol. Sci. 1971 261 : 305 10.
24. Lee RW, Huttner WB. Tyrosine O-sulfated proteins of PC12 pheochromocytoma cells and their sulfation by a tyrosylprotein sulfotransferase. J. Biol. Chem. 1983 258 : 11 326 34.
25. Sher E, Rosa P, Bassetti M, Zanini A. Immunolocalization of secretogranin II and insulin in a nerve growth factor-differentiated insulinoma cell line. Eur. J. Cell Biol. 1995 67 : 15 22.
26. Ottiger HP, Battenberg EF, Tsou AP, Bloom FE, Sutcliffe JG. 1B1075: A brain- and pituitary-specific mRNA that encodes a novel chromogranin/ secretogranin-like component of intracellular vesicles. J. Neurosci. 1990 10 : 3135 47.
27. Krisch K, Buxbaum P, Horvat G et al. Monoclonal antibody HISL-19 as an immunocytochemical probe for neuroendocrine differentiation. Its application in diagnostic pathology. Am. J. Pathol. 1986 123 : 100 8.
28. Mbikay M, Seidah NG, Chretien M. Neuroendocrine secretory protein 7B2: Structure, expression and functions. Biochem. J. 2001 357 : 329 42.
29. Ischia R, Lovisetti-Scamihorn P, Hogue-Angeletti R, Wolkersdorfer M, Winkler H, Fischer-Colbrie R. Molecular cloning and characterization of NESP55, a novel chromogranin-like precursor of a peptide with 5-HT1B receptor antagonist activity. J. Biol. Chem. 1997 272 : 11 657 62.
30. Helle KB. Some chemical and physical properties of the soluble protein fraction of bovine adrenal chromaffin granules. Mol. Pharmacol. 1966 2 : 298 310.
31. O'Connor DT, Bernstein KN. Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N. Engl. J. Med. 1984 311 : 764 70.
32. Hsiao RJ, Neumann HP, Parmer RJ, Barbosa JA, O'Connor DT. Chromogranin A in familial pheochromocytoma: Diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. Am. J. Med. 1990 88 : 607 13.
33. Nakamura E, Kaelin WG, Jr. Recent insights into the molecular pathogenesis of pheochromocytoma and paraganglioma. Endocr. Pathol. 2006 17 : 97 106.
34. Huynh TT, Pacak K, Wong DL et al. Transcriptional regulation of phenylethanolamine N-methyltransferase in pheochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Ann. N. Y. Acad. Sci. 2006 1073 : 241 52.
35. Huynh TT, Pacak K, Brouwers FM et al. Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Eur. J. Endocrinol. 2005 153 : 551 63.
36. Rao F, Keiser HR, O'Connor DT. Malignant and benign pheochromocytoma: Chromaffin granule transmitters and the response to medical and surgical treatment. Ann. N. Y. Acad. Sci. 2002 971 : 530 2.
37. O'Connor DT, Pandlan MR, Carlton E, Cervenka JH, Hslao RJ. Rapid radioimmunoassay of circulating chromogranin A: In vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin. Chem. 1989 35 : 1631 7.
38. Hsiao RJ, Mezger MS, O'Connor DT. Chromogranin A in uremia: Progressive retention of immunoreactive fragments. Kidney Int. 1990 37 : 955 64.
39. Canale MP, Bravo EL. Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. J. Clin. Endocrinol. Metab. 1994 78 : 1139 44.
40. Paulsen SD, Nghiem HV, Korobkin M, Caoili EM, Higgins EJ. Changing role of imaging-guided percutaneous biopsy of adrenal masses: Evaluation of 50 adrenal biopsies. AJR Am. J. Roentgenol. 2004 182 : 1033 7.
41. Jhala NC, Jhala D, Eloubeidi MA et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy of the adrenal glands: Analysis of 24 patients. Cancer 2004 102 : 308 14.
42. Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: A clinicopathologic and immunophenotypic study of 100 cases. Am. J. Surg. Pathol. 2002 26 : 551 66.
43. Kimura N, Watanabe T, Noshiro T, Shizawa S, Miura Y. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: A clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr. Pathol. 2005 16 : 23 32.
44. Gao B, Meng F, Bian W et al. Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas. Urology 2006 68 : 282 6.
45. Favier J, Plouin PF, Corvol P, Gasc JM. Angiogenesis and vascular architecture in pheochromocytomas: Distinctive traits in malignant tumors. Am. J. Pathol. 2002 161 : 1235 46.
46. Yon L, Guillemot J, Montero-Hadjadje M et al. Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors. J. Clin. Endocrinol. Metab. 2003 88 : 2579 85.
47. Kubota Y, Nakada T, Sasagawa I, Yanai H, Itoh K. Elevated levels of telomerase activity in malignant pheochromocytoma. Cancer 1998 82 : 176 9.
48. Boltze C, Mundschenk J, Unger N et al. Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma. J. Clin. Endocrinol. Metab. 2003 88 : 4280 6.
49. Salmenkivi K, Arola J, Voutilainen R et al. Inhibin/activin betaB-subunit expression in pheochromocytomas favors benign diagnosis. J. Clin. Endocrinol. Metab. 2001 86 : 2231 5.
50. Salmenkivi K, Haglund C, Ristimaki A, Arola J, Heikkila P. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. J. Clin. Endocrinol. Metab. 2001 86 : 5615 9.
51. Van Nederveen FH, Dinjens WN, Korpershoek E, De Krijger RR. The occurrence of SDHB gene mutations in pheochromocytoma. Ann. N. Y. Acad. Sci. 2006 1073 : 177 82.
52. Guo QM. DNA microarray and cancer. Curr. Opin. Oncol. 2003 15 : 36 43.
53. Anouar Y, Yon L, Guillemot J et al. Development of novel tools for the diagnosis and prognosis of pheochromocytoma using peptide marker immunoassay and gene expression profiling approaches. Ann. N. Y. Acad. Sci. 2006 1073 : 533 40.
54. Brouwers FM, Elkahloun AG, Munson PJ et al. Gene expression profiling of benign and malignant pheochromocytoma. Ann. N. Y. Acad. Sci. 2006 1073 : 541 56.
55. Sell S, Dunsford HA. Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am. J. Pathol. 1989 134 : 1347 63.
56. Sell S, Pierce GB. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab. Invest. 1994 70 : 6 22.
57. Elkahloun AG, Gaudet J, Robinson GS, Sgroi DC. In situ gene expression analysis of cancer using laser capture microdissection, microarrays and real time quantitative PCR. Cancer Biol. Ther. 2002 1 : 354 8.
58. Takahashi M, Yang XJ, McWhinney S et al. cDNA microarray analysis assists in diagnosis of malignant intrarenal pheochromocytoma originally masquerading as a renal cell carcinoma. J. Med. Genet. 2005 42 : e48.